The Latest

Big Data RWE often relies on fragmented, manipulated sources, with gaps, limited clinical relevance, and unclear ownership. It's costly, opaque, and often disconnected from real-world clinical insights.Solution:Circles Data offers a transparent, verifiable, and clinically relevant approach by sourcing directly from primary sources — physicians, patients, labs — within a secure, closed platform. It captures complete, longitudinal, and context-specific data, ensuring high integrity and meaningful insights.Key Advantages:‍Data Integrity and Verifiability: Direct, timestamped, unmanipulated data from trusted sources‍Completeness: Long-term, correlated patient cases with comprehensive outcomes‍Clinical Relevance: Focused, protocol-specific datasets aligned with real-world practice‍Strong Data Governance: Clear ownership, GCP compliance, and trusted collection methods‍Cost-Effective: Lower costs with minimal burden on clinicians and patients‍Equitable and Profitable: Physicians retain up to 80% of licensing value, boosting revenue & ownership‍Robust Reporting: Unlimited, included reports for deeper insightsChoose quality, transparency, and ownership. Choose Circles:

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:Regulatory Approvals: Over 11% of new pharmaceutical entities approved by the FDA between 2016 and 2024 were synthetic peptides. In 2023 alone, peptides accounted for 16.3% of novel therapeutics.Safety and Efficacy: While peptides offer significant benefits, challenges like immunogenicity and off-target effects need careful consideration. Metabolic Disorders: GLP-1 RAs like liraglutide, semaglutide, and tirzepatide are effective in managing type 2 diabetes and obesity, with additional cardiovascular benefits.Oncology: Peptide–drug conjugates (PDCs) and peptide vaccines are innovative approaches in cancer therapy, offering targeted treatment options. Cardiovascular and Neurological Diseases: Peptides show promise in managing heart failure and neurodegenerative diseases like Alzheimer's.Other Applications: Peptides are used in cosmetics for anti-aging effects and as antimicrobial agents to combat antibiotic resistance.

RegenMed is proud to announce that Dr. Dimitrios Tsoukas will act as Principal Investigator for a series of major Physicians-Owned Circles in the fast-evolving field of orthobioligics. These will be the first POCs in Greece. The initial POC Observational Protocol designed by Dr. Tsoukas will generate clinically and statistically significant datasets comparing safety and efficacy of PRP, ADSCs, and BMAC in knee osteoarthritis. His clinical surveys will not only track dosage, injection sites and other key treatment protocol information, but specific products used and delivery approaches. The resulting well-correlated datasets will thus represent substantial value to product manufacturers, payers, researchers, AI models and other licensees. Physician investigators participating in Dr. Tsoukas’s POCs will share 85% of all such license fees. In addition to senior positions in several orthopedic organizations such as ESSKA and ISAKOS, Dr. Tsoukas is the founder of IARMES, which includes other leading orthopedic practitioners in Europe and North America. Moreover, Dr. Tsoukas also teaches and practices in several countries outside of Greece, including Switzerland, Qatar, and the UAE. He is also an Adjunct Professor at the University of Nebraska, Lincoln. As such, RegenMed and Dr. Tsoukas expect to significantly expand international physician participation in his Circles.

Medical societies and advocacy groups (“Sponsors”) can now easily establish a mission-impactful and revenue-producing library of proprietary clinical data registries. This Circles Registry Program will materially advance the Sponsor’s charter goals, ethically generate new funding, and add real value to members.The healthcare data market is valued at $60 bn., growing at 20% per year. The physicians and patients whom medical societies and advocacy groups represent are the fundamental sources of that data. Yet, they receive virtually none of it. Circles Registries unlock that value for them. Read more.‍

Longevity medicine is redefining healthcare by shifting focus from treating disease to proactively extending healthspan — the years of life spent in good health. Grounded in geroscience, which targets the biological mechanisms of aging such as cellular senescence and mitochondrial dysfunction, this emerging field relies on personalized diagnostics and interventions including lifestyle optimization, supplements, and geroprotective drugs like metformin and rapamycin.Yet despite growing interest, longevity medicine faces critical challenges: fragmented data, unvalidated biomarkers, and a lack of large-scale human evidence. This is where real-world evidence (RWE) becomes transformative. RWE captures data from everyday clinical settings, enabling researchers to evaluate interventions across diverse populations and timeframes that randomized trials often cannot reach.RegenMed’s Physicians-Owned Circles (POCs) offer a breakthrough approach to generating validated RWE in longevity medicine. These decentralized, clinician-led data networks allow practitioners around the world to collaborate on observational studies tailored to specific conditions and interventions. Each POC adheres to regulatory standards and supports physicians in collecting actionable, clinically-relevant data with minimal burden.For clinicians, POCs offer benchmarking, professional development, and deeper patient engagement. For industry sponsors, they provide cost-effective, validated datasets that can accelerate regulatory approval and post-market surveillance. For the broader field, POCs build a scalable infrastructure to validate therapies, refine biological age clocks, and personalize treatment protocols.As the longevity industry continues to grow, the integration of validated RWE into clinical and research frameworks is essential. It is the key to moving from theory to practice, from hype to health impact. RegenMed’s model demonstrates how real-world data — when generated ethically and collaboratively — can unlock the full promise of longevity medicine for patients, providers, and society.